drugset / Trial / NCT04004442
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
Phase 1
Active not recruiting
19 enrolled
University of Oklahoma
Aravive, Inc. · collabEMD Serono · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety of avelumab and AVB-S6-500 and see what effects (good and bad) this combination treatment has on patients with advanced urothelial carcinoma.
Timeline
- Start
- 2020-02-17
- Primary completion
- 2022-04-07
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Batiraxcept | Protein / enzyme biologic | 5 mg/kg | Intravenous |
| Subject | Batiraxcept | Protein / enzyme biologic | 10 mg/kg | Intravenous |